All In Biotech

Drug Trial Radar · NCT07142811

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 5, 2025

Primary completion

Mar 2029

Study completion Jul 2030

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection

Conditions

  • Viral Hepatitis

Interventions

  • TobevibartDrug

    Tobevibart administered by subcutaneous injection

  • ElebsiranDrug

    Elebsiran administered by subcutaneous injection

  • BulevirtideDrug

    Bulevirtide administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48Time frame: Week 48
  2. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatmentTime frame: 24 Weeks after End of Treatment
  3. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 48Time frame: Week 48

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Brussels, Belgium

  • Investigative Site

    Brussels, Belgium

  • Investigative Site

    Edegem, Belgium

  • Investigative Site

    Sofia, Bulgaria

  • Investigative Site

    Sofia, Bulgaria

  • Investigative Site

    Stara Zagora, Bulgaria

  • Investigative Site

    Clichy, France

  • Investigative Site

    Créteil, France

  • Investigative Site

    Limoges, France

  • Investigative Site

    Rennes, France

  • Investigative Site

    Toulouse, France

  • Investigative Site

    Hanover, Germany

  • Investigative Site

    Chisinau, Moldova

  • Investigative Site

    Amsterdam, Netherlands

  • Investigative Site

    Rotterdam, Netherlands

  • Investigative Site

    Karachi, Pakistan

  • Investigative Site

    Karachi, Pakistan

  • Investigative Site

    Lahore, Pakistan

  • Investigative Site

    Rawalpindi, Pakistan

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Barcelona, Spain

  • Investigative Site

    Madrid, Spain

  • Investigative

    Valencia, Spain

  • Investigative Site

    Kyiv, Ukraine

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.